budesonide + ustekinumab

Budesonide + ustekinumab is a combination therapy consisting of two distinct pharmaceutical agents used in the management of Crohn’s disease. Budesonide is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties, primarily acting locally in the gut to reduce inflammation. Ustekinumab is a monoclonal antibody that targets and inhibits interleukin-12 (IL-12) and interleukin-23 (IL-23), key cytokines involved in inflammatory pathways, thereby modulating immune responses. This combination has been studied for its efficacy and safety compared to ustekinumab monotherapy in patients with moderate-to-severe Crohn’s disease. Clinical trials have shown that adding budesonide to ustekinumab does not significantly improve induction or maintenance of remission compared to ustekinumab alone, but the safety profile remains comparable[1][2][3].